The XGBoost model predicts hyperglycemia risk in psoriasis patients with high accuracy, achieving an AUC of 0.821 in the training set. A web-based calculator was developed to facilitate personalized ...

Nimbus Therapeutics enters research collaboration with Lilly to develop novel oral treatment for obesity and other metabolic diseases: Boston, Massachusetts Thursday, January 8, 2 ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines ...

A team of industry leaders and the University of North Dakota are targeting the nation’s $966 billion chronic disease ...

Dr. Vishal Sharma vishal.sharma@fulbrightmail.org Not long ago, the word “Artificial Intelligence (AI)” would bring to mind images of sci-fi robots, self-aware machines, or futuristic cities powered ...

Microbiome diagnostics and AI are redefining early disease detection, emphasizing the gut's impact on health and the ...

Addressing the microbiome's translational gap involves understanding biological complexity and developing function-driven, patient-specific interventions.

Successful implementation requires modern healthcare infrastructure, including reliable electricity, high-speed internet ...

Pharma industry experts indicate that strategy in 2026 is shifting to agentic AI, sustainable efficiency, and resilient supply chains to manage tariffs, regulations, and digitalization.

Oncology and tackling chronic issues like obesity are still the big drivers for growth in the biotech world. Combining ...